Varley C K, Holm V A
Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle.
J Am Acad Child Adolesc Psychiatry. 1990 Jan;29(1):137-40. doi: 10.1097/00004583-199001000-00022.
Six children with autism, who were treated with fenfluramine as part of a multi-center double-blind placebo-controlled crossover design study, were continued on an open trial of this medication. Follow-up evaluation of these children after 27 months indicated that numerous problems arose in the management of these children, most often resulting in discontinuation of the medication. Particularly noted were development of tolerance, appetite and weight problems, and requirements for other kinds of interventions including introduction of other psychotropic medications and change in custodial circumstances.
六名患有自闭症的儿童，作为多中心双盲安慰剂对照交叉设计研究的一部分接受了芬氟拉明治疗，之后继续对该药物进行开放性试验。对这些儿童27个月后的随访评估表明，在管理这些儿童的过程中出现了许多问题，最常见的结果是药物停用。特别值得注意的是耐受性的发展、食欲和体重问题，以及对其他类型干预措施的需求，包括引入其他精神药物和监护环境的改变。
